Our sites specialize in certain areas, products and regions. From our site in Alby-sur-Chéran, France we provide all markets except the U.S. with topicals—both over-the-counter (OTC) and prescription—including Differin®, Aklief® and Epiduo. Our largest production site, at Baie-D’Urfé, Canada, is focused on the global supply of Cetaphil®, with additional production of OTC and prescription medicine for the U.S. market. The Latin American market is predominantly served by our site in Hortolândia, Brazil. The plant in Uppsala, Sweden, specializes in aesthetics products, including Restylane®, one of our premium flagship brands.
SECURING SUPPLY WITH PROVEN RESILIENCE
While 70% of our units sold are produced in-house, we do outsource the production of selected products and formulations. We carefully assess third-party Contract Manufacturing Organizations (CMOs) against our supplier framework, ensuring they meet our rigorous standards.
By leveraging best-in-class technology, we are able to produce at a pace consistent with demand without compromising quality. Additionally, our unique Integrated Dermatology Strategy enables us to work on a common platform and therefore optimize our manufacturing and distribution footprint.
We have also announced significant expansion plans for our manufacturing capabilities to meet growing global demand for Injectable Aesthetics. Investment in a state-of-the-art facility in Uppsala will support both the distribution and development of products, and Galderma’s growth trajectory.
INDUSTRY-LEADING SAFETY AND QUALITY TRACK RECORD
All of Galderma’ manufacturing processes adhere to a variety of local and global laws and regulations, and all four of our sites have consistently passed all applicable material inspections.
These manufacturing plants are regularly audited by health authorities in their respective countries, including the U.S. Food and Drug Administration (FDA), Health Canada, the French National Agency for the Safety of Medicines and Health Products (ANSM) and Dekra. Our manufacturing facilities have also earned multiple certifications, such as ISO 14001 and ISO 45001, which reflect environmental, health and safety vigilance.
The key to our approach is continuous improvement. We hold regular quality and safety talks in our factories and continually analyze and learn from incidents at plants inside and outside the company. This has led to a constant and significant reduction in number and frequency of injuries.
Maintaining control over our production has enabled us to effectively implement and maintain sustainability measures. Three of our four factory sites use 100% renewable electricity from a combination of solar, wind, hydropower, geothermal, biofuel and biomass. Our fourth factory is on track to be powered by 100% renewable electricity by 2025. Currently, two of our four factories are certified Carbon Neutral, and all of them have achieved zero waste-to-landfill.
